BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Business

  Tessa Therapeutics Appoints Mr. Desmond Lim as CFO

  Mr. Lim has over 25 years of finance experience and has held multiple senior executive roles in the recent decade.

  December 11, 2017

   · 

  3 min read
• Business

  TransMed7, LLC Announces Inaugural Members of Its Business Advisory Board

  The TransMed7 BAB is composed of accomplished business experts offering innovative advice and dynamic perspectives that will contribute to the accomplishment of TransMed7’s tactical goals and strategic objectives.

  December 11, 2017

   · 

  6 min read
• Drug Development

  ADC Therapeutics Presents Interim Phase I Data From Its Novel Antibody-Drug Conjugate ADCT-402

  ADC Therapeutics announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia.

  December 11, 2017

   · 

  6 min read
• Drug Development

  NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333

  The pharmacokinetic data was in line with expectations and no adverse safety signals were detected.

  December 11, 2017

   · 

  5 min read
• Business

  Kimberly Blackwell, M.D., to Become VP of Early Phase Development and Immuno-Oncology at Lilly Oncology

  Eli Lilly today announced that Kimberly Blackwell, M.D. will join Lilly Oncology as VP of early phase development and immuno-oncology on March 12, 2018.

  December 11, 2017

   · 

  3 min read
• 

  Business

  Bay Area’s Ardelyx Forges $125M Deal With Fosun Pharma

  The agreement also provides Fosun Pharma the rights to commercialize tenapanor for other indications for which it is approved in the U.S.

  December 11, 2017

   · 

  6 min read
• Policy

  FDA Accepts BLA to Review Eli Lilly’s Galcanezumab for the Prevention of Migraine in Adults

  Lilly announced the submission of the BLA on its third-quarter earnings call in October 2017.

  December 11, 2017

   · 

  5 min read
• Business

  Ionis Pharma Licenses IONIS-HTT Rx to Partner Following Successful Phase I/II Study in Patients With Huntington’s Disease

  Roche will now be responsible for all development and commercial activities.

  December 11, 2017

   · 

  7 min read
• Policy

  Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA (aflibercept) Injection for Patients With Wet AMD

  Under the PDUFA, the goal for a standard review of an sBLA is ten months from submission for a target action date of August 11, 2018.

  December 11, 2017

   · 

  10 min read
• Business

  Radient Technologies Announces Master Services Agreement With Terra Life Sciences

  Radient Technologies Inc. announces the signing of a Master Services Agreement to produce cannabis extracts for the Terra Life Sciences group.

  December 11, 2017

   · 

  3 min read